IV Immunoglobulin (IVIg)



Background

IVIg is a concentrated solution of immune-supporting antibodies, given as an infusion. It is a blood product and must be managed as such.

IVIg is not routinely given in the ED - the usual setting is Wards 1A, 3A or 3D.

Departmental Position

  • In the ED, IVIg is only given for life-threatening indications, as outlined in table below
  • It should only be given if agreed by the CNM, and administered in Resus or Majors
  • Medical and nursing staff should seek support if unfamiliar with prescribing or administering IVIg

Indications

Indications where IVIg treatment must not be delayed
Specialty Indication
Haematology Severe thrombocytopaenia in ITP with platelets <10
Severe refractory AIHA with Hb <7
Rheumatology Myositis (particularly with dysphagia)
Haemophagocytic lymphohistiocytosis (HLH)
Neurology Severe Guillain-Barré syndrome
Relapse of CIDP
Myasthenia Gravis crisis - give within 12 hours of admission

Contraindications

  • Patient is acutely unwell with untreated infection - wait until infection is controlled and the patient is improving clinically

Prescriber Protocol

  • Verbal consent, documented in the notes - indication, possible side-effects, and blood component/haemovigilance discussed
  • Pre-treatment bloods: FBC, U&E, creatinine must be back before treatment; LFTs and HepB/C/HIV serology also taken
  • Prescribe on Form 15B (Intravenous Immunoglobulin Prescription and Administration Record)

Caution

  • Kiovig® and Flebogamma® are not interchangeable
  • Contact Pharmacy to confirm stock, dose rounding, and the patient's IVIg brand history

Dose

Dose is calculated using an adjusted body weight for overweight or obese adults, not actual weight:

  • Dosing weight = IBW + [0.4 × (Actual weight − IBW)]  (if actual weight is less than IBW, use actual weight)
  • IBW (Devine formula, using cm):
    • Male: 50 + 0.91 × (height cm − 152.4)
    • Female: 45.5 + 0.91 × (height cm − 152.4)

Round the dose down to the nearest whole vial to minimise waste - never use part vials in adults. If the dose is split over several days, the daily amount may vary.

Infusion rate
Stage Rate
Start (first 30 min) 0.5 ml/kg/hr
Then, every 30 min as tolerated increase by 0.5 ml/kg/hr
Maximum 6 ml/kg/hr (rarely >4 ml/kg/hr for inpatients)

The Alberta Health Services IVIg calculator can be used to assist with calculations

Two nurses must independently double-check the dose and preparation before it is connected.


Monitoring

  • Observations (temp, pulse, sats, BP) at the start, at every rate change, and at the end - document on the INEWS chart
  • Ensure adequate hydration before starting, and monitor urine output and creatinine throughout
  • Watch for signs and symptoms of thrombosis
  • First infusion, a switched product, or a long gap since the last dose: monitor throughout and for 1 hour after. All other patients: observe for at least 20 minutes after

Adverse Reaction

  • Stop the infusion immediately
  • Contact a member of the medical team
  • Please report any suspected adverse reactions


Content by Dr Ciara McGlade 14/11/2025. Last review Dr Amy Brennan 14/09/2026.